Oncogenic induction of cellular high CpG methylation by Epstein-Barr virus in malignant epithelial cells

Chinese Journal of Cancer

Volumn 33, Issue 12, 2014, Pages 604-608

  Li, Lili ^a   Zhang, Yuan ^a   Guo, Bing Bing ^a   Chan, Francis K L ^b   Tao, Qian ^b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

CpG methylation; DNA methyltransferase; Epstein Barr virus; Gastric cancer; Nasopharyngeal carcinoma; Tumor suppressor gene

Indexed keywords

VIRAL PROTEIN;

CPG ISLAND; DNA METHYLATION; EPIGENETICS; EPITHELIUM CELL; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; METHYLATION; NASOPHARYNX TUMOR; PROMOTER REGION; STOMACH TUMOR;

CPG ISLANDS; DNA METHYLATION; EPIGENOMICS; EPITHELIAL CELLS; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; METHYLATION; NASOPHARYNGEAL NEOPLASMS; PROMOTER REGIONS, GENETIC; STOMACH NEOPLASMS; VIRAL PROTEINS;

EID: 84909967043     PISSN: None     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.014.10191     Document Type: Review

References (57)

1. [1] Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer, 2004,4:757-768.
2. [2] Kieff E. Current perspectives on the molecular pathogenesis of virus-induced cancers in human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst Monogr, 1998,23:7-14.
3. [3] Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol, 2002,12:431-441.
4. [4] Tao Q, Young LS, Woodman CB, et al. Epstein-Barr virus (EBV) and its associated human cancers—genetics, epigenetics, pathobiology and novel therapeutics. Front Biosci, 2006,11:2672-2713.
5. [5] Tao Q, Chan AT. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med, 2007,9:1-24.
6. [6] Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell, 2004,5:423-428.
7. [7] Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005,55:74-108.
8. [8] Osato T, Imai S. Epstein-Barr virus and gastric carcinoma. Semin Cancer Biol, 1996,7:175-182.
9. [9] Jones PA, Baylin SB. The epigenomics of cancer. Cell, 2007,128:683-692.
10. [10] Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet, 2002,3:415-428.
11. [11] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell, 2011,144:646-674.
12. [12] Baylin SB, Ohm JE. Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction? Nat Rev Cancer, 2006,6:107-116.
13. [13] Yu DH, Waterland RA, Zhang P, et al. Targeted p16ink4a epimutation causes tumorigenesis and reduces survival in mice. J Clin Invest, 2014,124:3708-3712.
14. [14] Kaneda A, Matsusaka K, Aburatani H, et al. Epstein-Barr virus infection as an epigenetic driver of tumorigenesis. Cancer Res, 2012,72:3445-3450.
15. [15] Matsusaka K, Kaneda A, Nagae G, et al. Classification of Epstein- Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res, 2011,71:7187-7197.
16. [16] Li LL, Shu XS, Wang ZH, et al. Epigenetic disruption of cell signaling in nasopharyngeal carcinoma. Chin J Cancer, 2011,30:231-239.
17. [17] Li HP, Leu YW, Chang YS. Epigenetic changes in virus-associated human cancers. Cell Res, 2005,15:262-271.
18. [18] Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell, 1986,47:883-889.
19. [19] Wang K, Yuen ST, Xu J, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet, 2014,46:573-582.
20. [20] The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature, 2014,513:202-209.
21. [21] Lin DC, Meng X, Hazawa M, et al. The genomic landscape of nasopharyngeal carcinoma. Nat Genet, 2014,46:866-871.
22. [22] Kang GH, Lee S, Kim WH, et al. Epstein-Barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am J Pathol, 2002,160:787-794.
23. [23] Fukayama M, Hino R, Uozaki H. Epstein-Barr virus and gastric carcinoma: virus-host interactions leading to carcinoma. Cancer Sci, 2008,99:1726-1733.
24. [24] Chang MS, Uozaki H, Chong JM, et al. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin Cancer Res, 2006,12:2995-3002.
25. [25] Zhao J, Liang Q, Cheung KF, et al. Genome-wide identification of Epstein-Barr virus-driven promoter methylation profiles of human genes in gastric cancer cells. Cancer, 2013,119:304-312.
26. [26] Jin H, Wang X, Ying J, et al. Epigenetic silencing of a Ca(2+)- regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers. Proc Natl Acad Sci U S A, 2007,104:12353-12358.
27. [27] Lo KW, Kwong J, Hui AB, et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res, 2001,61:3877-3881.
28. [28] Qiu GH, Tan LK, Loh KS, et al. The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. Oncogene, 2004,23:4793-4806.
29. [29] Ying J, Li H, Seng TJ, et al. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene, 2006,25:1070-1080.
30. [30] Cheng Y, Geng H, Cheng SH, et al. KRAB zinc finger protein ZNF382 is a proapoptotic tumor suppressor that represses multiple oncogenes and is commonly silenced in multiple carcinomas. Cancer Res, 2010,70:6516-6526.
31. [31] Birdwell CE, Queen KJ, Kilgore P, et al. Genome-wide DNA methylation as an epigenetic consequence of Epstein-Barr virus infection of immortalized keratinocytes. J Virol, 2014,88:11442-11458.
32. [32] Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene, 2003,22:5108-5121.
33. [33] Ambinder RF, Robertson KD, Tao Q. DNA methylation and the Epstein-Barr virus. Semin Cancer Biol, 1999,9:369-375.
34. [34] Seto E, Ooka T, Middeldorp J, et al. Reconstitution of nasopharyngeal carcinoma-type EBV infection induces tumorigenicity. Cancer Res, 2008,68:1030-1036.
35. [35] Fukayama M, Hayashi Y, Iwasaki Y, et al. Epstein-Barr virusassociated gastric carcinoma and Epstein-Barr virus infection of the stomach. Lab Invest, 1994,71:73-81.
36. [36] Imai S, Koizumi S, Sugiura M, et al. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci U S A, 1994,91:9131-9135.
37. [37] Uozaki H, Fukayama M. Epstein-Barr virus and gastric carcinoma— viral carcinogenesis through epigenetic mechanisms. Int J Clin Exp Pathol, 2008,1:198-216.
38. [38] Strong MJ, Xu G, Coco J, et al. Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy. PLoS Pathog, 2013,9:e1003341.
39. [39] Pfeffer S, Zavolan M, Grasser FA, et al. Identification of virusencoded microRNAs. Science, 2004,304:734-736.
40. [40] Cai X, Schafer A, Lu S, et al. Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog, 2006,2:e23.
41. [41] You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell, 2012,22:9-20.
42. [42] Schuettengruber B, Cavalli G. Recruitment of polycomb group complexes and their role in the dynamic regulation of cell fate choice. Development, 2009,136:3531-3542.
43. [43] Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Develop, 2011,25:1010-1022.
44. [44] Tsai CN, Tsai CL, Tse KP, et al. The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc Natl Acad Sci U S A, 2002,99:10084-10089.
45. [45] Tsai CL, Li HP, Lu YJ, et al. Activation of DNA methyltransferase 1 by EBV LMP1 involves c-Jun NH(2)-terminal kinase signaling. Cancer Res, 2006,66:11668-11676.
46. [46] Siouda M, Frecha C, Accardi R, et al. Epstein-Barr virus downregulates tumor suppressor DOK1 expression. PLoS Pathog, 2014,10:e1004125.
47. [47] Hino R, Uozaki H, Murakami N, et al. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res, 2009,69:2766-2774.
48. [48] Kong QL, Hu LJ, Cao JY, et al. Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog, 2010,6:e1000940.
49. [49] Leight ER, Sugden B. EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus. Rev Med Virol, 2000,10:83-100.
50. [50] Sugden B, Warren N. A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA- 1, a viral protein required for viral DNA replication during latent infection. J Virol, 1989,63:2644-2649.
51. [51] Kanda T, Horikoshi N, Murata T, et al. Interaction between basic residues of Epstein-Barr virus EBNA1 protein and cellular chromatin mediates viral plasmid maintenance. J Biol Chem, 2013,288:24189-24199.
52. [52] Lu F, Wikramasinghe P, Norseen J, et al. Genome-wide analysis of host-chromosome binding sites for Epstein-Barr virus nuclear antigen 1 (EBNA1). Virol J, 2010,7:262.
53. [53] Canaan A, Haviv I, Urban AE, et al. EBNA1 regulates cellular gene expression by binding cellular promoters. Proc Natl Acad Sci U S A, 2009,106:22421-22426.
54. [54] Esteller M. Epigenetics in cancer. N Engl J Med, 2008, 358:1148-1159.
55. [55] Baylin SB, Jones PA. A decade of exploring the cancer epigenome—biological and translational implications. Nat Rev Cancer, 2011,11:726-734.
56. [56] Chan AT, Tao Q, Robertson KD, et al. Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. J Clin Oncol, 2004,22:1373-1381.
57. [57] Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov, 2011,1:598-607.